AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, ...

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

Acquisition of EsoBiotec completed AstraZeneca today announced the successful completion of the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its ...

Findings from a first-of-its-kind virtual trial in pulmonary medicine, conducted at Rutgers and many other institutions, ...

Findings from a first-of-its-kind virtual trial in pulmonary medicine, conducted at Rutgers and many other institutions, ...

The Gross Law Firm issues the following notice to shareholders of Canopy Growth Corporation . Shareholders who purchased shares ...

Absolute Security, a leader in enterprise resilience, today announced new Extreme Resilience capabilities available in Rehydrate, an Absolute Resilience Platform module. Rehydrate enables remote ...

The BATURA trial compared the use of Airsupra to albuterol, a commonly used rescue medicine in the US. The trial showed that ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol, the ...

Late-breaking findings on pulmonology, critical care, and sleep medicine will be presented at the American Thoracic Society ...